This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Updated: February 2025 "Medicine is a science of uncertainty and an art of probability." - William Osler. MWA Consulting: Is dedicated to upholding GXP quality and regulatory compliance in the pharmaceutical, medical device, and biotechnology industries.
The pharmaceutical and biotechnology industries are at the cusp of a transformative era in 2025, driven by cutting-edge innovation, evolving regulations, and increasing market pressures. “The pharmaceutical and biotechnology industries are at a pivotal moment, where cutting-edge innovation meets increasing market demands.
The landscape of global molecular biomarkers is rapidly evolving, driven by advancements in biotechnology and the increasing demand for personalized medicine. Companies must navigate regulatory challenges, leverage AI for biomarker precision, and invest in strategicpartnerships to stay ahead.
13 th February 2025 Frost & Sullivan recently analyzed the biotechnology contract research organization (CRO) industry and, based on its findings, recognizes Southern Star Research with the 2024 Asia-Pacific Competitive Strategy Leadership Award. SAN ANTONIO, TX.
February 5, 2025 Frost & Sullivan recently assessed the clinical sample analysis services industry and, based on its findings, recognizes Global Clinical Central Lab ( GCCL ) with the 2025 Asia-Pacific Customer Value Leadership Award. SAN ANTONIO, TX.
We organize all of the trending information in your field so you don't have to. Join 61,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content